Endoscopic Submucosal Dissection Market
The global endoscopic submucosal dissection market in terms of revenue was estimated to be worth $347 million in 2022 and is poised to reach $483 million by 2027, growing at a CAGR of 6.9% from 2022 to 2027.
The increasing incidence of target diseases such as cancer is expected to accelerate the need for endoscopic procedures, which, in turn, will propel the growth of this market in the coming years. Due to high investment, training, and maintenance costs, endoscopic submucosal dissection procedures are typically expensive. Additionally, in most of the Asian countries, there is little or no government reimbursement for endoscopic submucosal dissection procedures, which is expected to restrain the market growth to some degree in the coming years.
Endoscopic Submucosal Dissection Market Dynamics
Driver: Geriatric population growth
Endoscopic submucosal dissection (ESD) is becoming increasingly popular as the prevalence of age-related diseases such as gastric cancer and GI bleeding rises. The elderly are more prone to several ailments due to weakened immune systems and decreased physical activity. The elderly population is expected to approach 1.5 billion by 2050, boosting the demand for endoscopic submucosal dissection. The increased cancer prevalence is also driving the endoscopic submucosal dissection market forward.
Restraint: ESD techniques have a high overhead cost with limited reimbursements.
The high overhead of ESD procedures with limited reimbursements is a major restraint to the growth of the endoscopic submucosal dissection market. Indeed, endoscopic dissection of the submucosa is a complex and time-consuming procedure and the costs associated with it are quite high. This makes the procedure unaffordable for many patients. Moreover, reimbursement levels for endoscopic submucosal dissection are quite low, which is another major factor preventing its adoption. This factor is particularly important in developing countries where the health care infrastructure is not well developed.
Opportunity: Endoscopic submucosal dissection methods are expected to be more widely used and preferred in developing nations.
Endoscopic submucosal dissection (ESD) operations are becoming more popular in developing nations, which is projected to boost the growth of the worldwide endoscopic submucosal dissection market. This is because endoscopic operations are becoming more accessible and cost-effective equipment is becoming more available in these areas. Furthermore, rising awareness of ESD procedures and the availability of experienced individuals in these nations are projected to fuel market expansion.
The increased frequency of gastrointestinal disorders including esophageal and gastric cancer is expected to increase demand for ESD operations in emerging countries. Increased government attention on healthcare infrastructure and access improvements, such as the implementation of universal healthcare systems, are likely to fuel market expansion even further. Furthermore, the rising focus of medical device makers on extending their presence in these areas is expected to considerably boost market growth.
Furthermore, the increasing number of mergers and acquisitions, strategic partnerships, and product launches by market participants is likely to generate profitable prospects for the worldwide endoscopic submucosal dissection market to develop.
Challenges: Post-operative infection risk
Endoscopic submucosal dissection is a relatively new procedure used for the treatment of early gastrointestinal cancers, regardless of lesion size and configuration. It has gradually gained popularity due to its minimally invasive nature. Compared to conventional endoscopic resection, endoscopic submucosal dissection is a more complex procedure and requires a higher level of technical skill. It is therefore associated with a higher complication rate. Postoperative fever is one of the most common complications. During ESD, the injection needle catheter is passed through the contaminated endoscopic channel and can directly inoculate bacteria into the bloodstream during submucosal injection. Additionally, ESD can produce mucosal defects. Bacteremia and/or endotoxemia can occur when submucosa and musculoskeletal cells are exposed to the native bacterial flora of the gastrointestinal tract. Bacteremia could be caused by bacterial translocation of endogenous microbial flora through the injured mucosa into the bloodstream during the endoscopy procedure. These infectious complications have been reported to be infrequent and transient in both REM and ESD of the stomach and colon.
Based on product, During the projection period, the knives category will expand at the fastest CAGR in the endoscopic submucosal dissection market.The market is divided into knives, tissue retractors, forceps/forceps, injectable agents, gastroscopes and colonoscopes, and other items based on product. In 2027, the knife category will continue to lead the market, increasing at the fastest CAGR throughout the forecast period. Endoscopic submucosal dissection involves circumscribing the lesions with a knife to entirely separate the lesion from the remainder of the normal mucosa. There are several knives on the market, and the industry has progressed significantly over the last two decades as efforts to increase efficiency, safety, and cost-effectiveness have been made.
Based on indications, During the projection period, the esophageal cancer segment will expand at the fastest CAGR in the endoscopic submucosal dissection market.
The market is divided into three sections based on indication: stomach cancer, colon cancer, and esophageal cancer. During the projection period, the esophageal cancer sector will increase at the fastest CAGR. The prevalence of superficial esophageal cancer (SEC) is rising, particularly in Asian nations such as Japan, where upper digestive tract cancer monitoring is frequent.
Based on end user, During the forecast period, the hospitals segment will grow at the fastest CAGR in the endoscopic submucosal dissection market.
The hospitals category will grow at the quickest CAGR throughout the forecast period. Hospital investments and government incentives are two key factors driving the growth of this industry.
In 2022, North America is predicted to hold the greatest proportion of the endoscopic submucosal dissection market.
North America is expected to account for the largest share, owing to the country's high healthcare spending, favourable reimbursement policies for endoscopic procedures, an increased incidence of cancer, ongoing research on endoscopy techniques, and a high number of FDA approvals for endoscopy systems.
The prominent players in the endoscopic submucosal dissection market are Olympus Corporation (Japan), Boston Scientific Corporation (US), FUJIFILM Holdings Corporation (Japan), Sumitomo Bakelite Co., Ltd. (Japan), Creo Medical (UK), Medtronic (Ireland), MTW EndoskopieManufaktur (Germany), HOYA Corporation (Japan), Ovesco Endoscope AG (Germany), Zeon Medical Inc. (Japan), KARL STORZ SE & Co. KG (Germany), ConMed Corporation (US), Micro-tech Endoscopy (China), Cook Group (US), Steris PLC (Ireland), Leo Medical Co., Ltd. (China), ErbeElektromedizin GmbH (Germany), Taewoong Medical (South Korea), DCC Healthcare (Ireland), Kossen Co., Ltd. (South Korea), InnovaMedica SPA (Italy), Jiangsu Vedkang Medical Science and Technology Co., Ltd. (China), Hangzhou AGS MedTech Co., Ltd. (China), and Beijing ZKSK Technology Co., Ltd. (China).
Endoscopic Submucosal Dissection Market Report Scope
This report categorizes the global endoscopic submucosal dissection market into the following segments and subsegments:
By Product
- Gastroscopes And Colonoscopes
- Knives
- Injection Agents
- Tissue Retractors
- Graspers/Clips
- Other Products
By Indication
- Stomach Cancer
- Colon Cancer
- Esophageal Cancer
By End User
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Other End Users
By Region
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Rest of Asia Pacific
- Latin America
- Middle East and Africa
Recent Developments
In recent years, endoscopic submucosal dissection (ESD) has become increasingly popular as a treatment option for the resection of early gastric cancers. ESD is a minimally invasive endoscopic procedure that uses a special knife and suction device to cut and remove cancerous or precancerous tissue from the gastrointestinal tract. It is a safe, effective and very precise method of removing tumors from the stomach, esophagus and rectum without requiring major surgery. Compared to other therapies such as endoscopic mucosal resection, ESD is more precise and results in less bleeding and shorter recovery times. It has also been shown to be effective in the treatment of early gastric cancer, reducing gastric cancer death rates. Additionally, it has been used to treat early colorectal cancer, benign lesions, and dysplasia with high success rates. With its increasing use, ESD is revolutionizing the treatment of early gastric and colorectal cancers and other gastrointestinal diseases.
- In March 2021, FUJIFILM Holdings Corporation (Japan) bought Hitachi, Ltd.'s Diagnostic Imaging-related Business (the Business). This acquisition aided FUJIFILM Corporation's growth of its medical systems business.
- Olympus Corporation (Japan) bought Quest Innovations B.V. (Netherlands) in January 2021. Olympus was able to expand its surgical endoscopy capabilities and incorporate Quest's advanced FIS capabilities into its full medical imaging platform as a result of the purchase.
- Creo Medical Group PLC (UK) will purchase Boucart Medical SRL (Belgium) in November 2020. Creo Medical Group has finalised the purchase of Boucart Medical SRL, Belgium and Luxembourg's biggest independent provider of gastrointestinal endoscopy supplies.